Boston Scientific Corp.’s intent to acquire Penumbra Inc. for $14.5 billion will not only allow it to expand its minimal invasive care portfolio in areas such as embolization and peripheral vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results